

THE POTENTIAL HARMS OF PERSONAL LUBRICANTS

OS POTENCIAIS DANOS DOS LUBRIFICANTES PESSOAIS

Cassandra Laurie¹ , Eduardo Franco¹ 

INTRODUCTION

Over 100 years ago, the first personal lubricant became available when a surgical lubricant was re-formulated into a non-sterile, publicly available version, albeit by prescription⁽¹⁾. The lubricant became commercially available in the 1980s, with most sales occurring in Brazil, Canada, and the United States (US). Currently in the US, personal lubricant use is common among women⁽²⁾, men⁽³⁾, and, specifically, gay and bisexual men⁽⁴⁾, groups in which 66, 70, and 90% have ever used a lubricant, respectively. Water-based lubricants can be used alongside condoms during sexual activities, including vaginal-penile and penile-anal sex to ensure adequate lubrication⁽⁵⁾ and comfort, to reduce condom breakage during anal sex⁽⁶⁾, and to reduce friction.

In the US and Europe, personal lubricants are classified as class II or class IIa – “medical devices”, respectively. In the US, new or modified lubricants must submit 510(k) clearance to the Food and Drug Administration (FDA), demonstrate safety and effectiveness, and show that they are reasonably equivalent to a legally marketed device. In both the US and Europe, the products are subjected to cytotoxicity, irritation, and sensitization testing, as well as acute toxicity testing (US only). In Canada, personal lubricants are classified as “cosmetics”. Manufacturers must complete a Cosmetic Notification Form and provide details on ingredients (known, restricted, prohibited, unknown).

Regardless of the lubricant testing regulations, several studies have assessed lubricant safety since the late 1990s⁽⁷⁻¹⁴⁾. These evaluations demonstrated epithelial damage and irritation, raising concerns regarding safety, and leading to the release of an advisory note in 2012⁽¹⁵⁾. This advisory note recommended use of lubricants that are iso-osmolar, free of polyquaternium-15, and free of nonoxynol-9. Given the concerns regarding the safety of personal lubricants, we reviewed articles reporting on the safety of commercially available lubricants and the association between lubricant use and bacterial vaginosis (BV) and/or sexually transmitted infections (STIs).

NONOXYNOL-9

Cytotoxicity and epithelial damage have been reported after application of a nonoxynol-9 personal lubricant. In 2000, Phillips et al. tested two nonoxynol-9 containing lubricants in humans (n=4, 75% men); their application (namely K-Y[®]Plus and ForPlay[®]) caused extensive exfoliation of rectal epithelium⁽⁸⁾. Similarly, in 2004, Sudol and Phillips tested lubricants in a rectal mouse model⁽¹⁰⁾. Several lubricants tested caused epithelial sloughing, with K-Y[®]Plus (nonoxynol-9-containing) causing the most damage. K-Y[®]Plus also enhanced rectal herpes simplex virus 2 (HSV-2) infection. Nonoxynol-9 use is

associated with genital lesions⁽¹⁶⁾, and a randomized controlled trial consisting of female sex workers demonstrated that use of a nonoxynol-9 gel increased the risk of human immunodeficiency virus 1 (HIV-1) acquisition compared to the use of a placebo gel⁽⁹⁾. The risk was even higher among the most frequent users. Nonoxynol-9 use is not recommended⁽¹⁷⁾. Nevertheless, nonoxynol-9 containing products are still permitted by the FDA, as long as they adhere to specific labelling requirements⁽¹⁸⁾.

OSMOLALITY

There is some evidence suggesting the osmolality of personal lubricants is associated with irritation and epithelial damage. In 2007, Fuchs et al. conducted a small study of 10 men who have sex with men (MSM), including men living with and without HIV⁽¹¹⁾. The authors found that rectal application of hyperosmolar lubricant led to greater epithelial injury than an iso-osmolar lubricant. In 2008, Adriaens and Remon tested several lubricants on slugs⁽¹²⁾. The lubricants were found to cause mild, moderate, and severe irritation corresponding to the osmolality of lubricant used. However, in contrast to Adriaens and Remon’s study in slugs⁽¹²⁾, a study by Cunha et al. in cells showed no correlation between osmolality and cytotoxicity⁽¹⁹⁾. This study suggests the individual ingredients may be more important than the osmolality level itself.

In a human model of the vaginal epithelium, lubricants with an osmolality >1,500 mOsm/kg led to reductions in the epithelial barrier and damage to the structure of the vaginal model⁽²⁰⁾. Similarly, in 2019, Wilkinson et al. tested the effect of lubricants with a range of osmolality values (270–10,300 mOsm/kg) in a human vaginal epithelial cell monolayer and a three-dimensional model⁽²¹⁾. The application of hyperosmolar lubricants was cytotoxic in both systems, and there was a correlation between osmolality and cytotoxicity. In addition, the hyperosmolar lubricants led to a reduction in cell viability and to changes in morphology, and some lubricants also altered inflammatory mediators⁽²¹⁾. The models to assess safety of lubricants are becoming increasingly sophisticated, which allow for testing of lubricant safety in more biologically relevant models.

BACTERIAL VAGINOSIS

Several cross-sectional and cohort studies in women have evaluated the association between lubricant use/type and bacterial vaginosis (BV), a common vaginal infection. A 2007 cross-sectional study reported an association between petroleum jelly use and BV, as well as saliva use and BV⁽²²⁾; however, in a cohort study of the same population, petroleum jelly and saliva were not found to be independent predictors of BV⁽²³⁾. The authors did not assess commercial other lubricants use. An additional cross-sectional study from

¹Division of Cancer Epidemiology, McGill University – Montreal, Canada.

2010 reported an association between vaginal lubricant use in the last three months and BV⁽²⁴⁾. This was confirmed in a small cohort study (n=29) by Brotman et al. in 2010. The authors found lubricant use in the last 24 hours to be associated with BV⁽²⁵⁾. However, a larger cohort study by Brown et al. (n=141) did not find an association between commercial lubricant or oil use and BV⁽²⁶⁾. This study did find, however, an increased risk of BV among petroleum jelly users compared to non-users. Altogether, it is unclear the level of risk of BV associated with different lubricant use (commercial lubricants, oil, saliva, petroleum jelly, etc.). Clarifying the association between lubricant use with BV is needed, as BV may increase the risk of gonorrhea and chlamydia⁽²⁷⁾, herpes⁽²⁸⁾, trichomonas⁽²⁹⁾, and HIV⁽³⁰⁾.

HERPES SIMPLEX VIRUS 2

The association between lubricants and HSV-2 susceptibility was assessed in three studies. Two studies in 1998⁽⁷⁾ and 2004⁽¹⁰⁾, respectively, used a rectal mouse model to test the effect of personal lubricants. Another study in 2010 assessed the effect of personal lubricants in a vaginal mouse model⁽¹³⁾. Phillips and Zacharopoulos tested the effect of nonoxynol-9-containing personal lubricants, which showed enhancement of rectal HSV-2 infection⁽⁷⁾. As mentioned previously, Sudol and Phillips's 2004 study tested lubricants in a rectal mouse model⁽¹⁰⁾. Two hyperosmolar lubricants, K-Y Plus[®] (nonoxynol-9-containing) and Astroglide[®], caused significantly and non-significantly enhanced rectal HSV-2 infection, respectively. A later evaluation in 2010 assessed different topical products, including a personal lubricant (K-Y[®] Warming Jelly), effect on vaginal HSV-2 susceptibility, demonstrating enhanced susceptibility to infection after K-Y[®] Warming Jelly application⁽¹³⁾. As mentioned previously, the spermicide nonoxynol-9 is no longer recommended⁽¹⁷⁾; however, K-Y[®] Warming Jelly is still commercially available.

GONORRHEA, CHLAMYDIA, AND SYPHILIS

In 2012, Gorbach et al. evaluated the association between lubricant use and prevalent rectal STIs (chlamydia and/or gonorrhea) among men and women practicing receptive anal intercourse (n=348)⁽³¹⁾. The authors found lubricant use is associated with prevalence of rectal STI (odds ratio=2.98, 95%CI 1.09–8.15). Additionally, more rectal STIs were detected among exclusive water-based lubricant users compared to other users (6.1% versus 2.7%). In contrast to the Gorbach et al. (2012) study, a smaller study (n=146) by Maierhofer et al. in 2016 found consistent lubricant use was not associated with prevalence of rectal STI (chlamydia and/or gonorrhea) among MSM, prevalence ratio=0.78 (95%CI 0.50–1.22)⁽³²⁾. A limitation of the study is that while the authors identified the brand name of the lubricant used, they did not reveal the type of lubricant used (i.e. water-, oil-, or silicone-based). Some of the brand-name lubricants were associated with rectal STI, although this could be due to multiple testing. While the studies by Gorbach et al.⁽³¹⁾ and Maierhofer et al.⁽³²⁾ have differing results, a cohort study assessing STIs acquired over time provides additional evidence for the association between lubricant use and STIs⁽³³⁾. In 2020, Blair et al. reported cross-sectional data from a longitudinal cohort study (n=313) evaluating the association between lubricant use and laboratory-confirmed STI

(gonorrhea, chlamydia, and/or syphilis) among MSM living with and without HIV⁽³³⁾. The authors found an association between consistent lubricant use and STI diagnosis (adjusted odds ratio=1.81; 95%CI 1.11–2.96). These findings suggest lubricants may increase the risk of rectal STI, which is especially relevant as some STIs may be associated with an increased risk of HIV acquisition⁽³⁴⁻³⁶⁾.

HUMAN IMMUNODEFICIENCY VIRUS

In 2011, Begay et al. tested 41 personal lubricants⁽¹⁴⁾. In vitro testing demonstrated that 4 of the 41 commercially available lubricants tested enhanced HIV-1 infection. Most of these lubricants were hyperosmolar and 3 contained polyquaternium-15, indicating a potential risk for these products. A year later, Dezzutti et al. reported results of a study testing the safety and anti-HIV-1 activity of water-based lubricants in cell lines and explant cultures of the colorectum and ectocervix⁽³⁷⁾. Of the 10 water-based lubricants tested, 6 were hyperosmolar and exhibited damage to cervical and colorectal explant tissues. Astroglide[®], a highly hyperosmolar lubricant containing polyquaternium-32, was not found to enhance HIV-1 replication in the tissues. While another hyperosmolar lubricant, K-Y Jelly[®], demonstrated a reduction in HIV-1 replication, the authors attributed this to a reduction in tissue viability. In 2015, Vishwanathan et al. demonstrated that while rectal application of a highly hyperosmolar lubricant (containing polyquaternium-15) leads to epithelial sloughing, this lubricant does not increase risk of simian-human immunodeficiency virus in macaque⁽³⁸⁾. In 2019, Rao et al. reported on correlates of water-based lubricants among MSM living with and without HIV⁽³⁹⁾. The authors did not find an association between water-based lubricant use and HIV diagnosis. To summarize these findings: while an early study from 2011 showed enhancement of HIV-1 infection in cells⁽¹⁴⁾, an ex vivo⁽³⁷⁾, animal⁽³⁸⁾ and observational study in humans⁽³⁹⁾ did not demonstrate an association between lubricant use and HIV susceptibility and/or infection.

PUBLIC HEALTH POLICY IMPLICATIONS

In 2012, the World Health Organization (WHO) issued an advisory note for personal lubricant procurement⁽¹⁵⁾. The report suggested an ideal osmolality of below 380 mOsm/kg, but on an interim basis, 1,200 mOsm/kg would suffice. The report also recommended avoiding polyquaternium-15; however, four years later, in a report from the November 2016 “Global consultation on personal lubricants” meeting, the organization no longer restricted use of polyquaternium-15 based on the lack of evidence of harm⁽⁴⁰⁾, highlighting the challenge in determining which ingredient in the lubricant actually causes damage, irritation, and/or increased risk of STIs. For osmolality, the original statement was retained: 380 mOsm/kg would be the ideal osmolality for personal lubricants, but the use of lubricants up to 1,200 mOsm/kg for procurement agencies was still supported. Hyperosmolar lubricants tend to be more harmful to the epithelium than their iso-osmolar counterparts. Nevertheless, the WHO/United Nations Population Fund (UNFPA) issued in July 2019 a draft report on “Specifications for plain lubricants”, in which it states that the osmolality cut-off of 1200 mOsm/kg is under revision⁽⁴¹⁾.

There does appear to be some level of risk associated with personal lubricant use. Some earlier recommendations have been either

reverted (polyquaternium-15) or are under revision (osmolality limit). This indicates the evolving and changing recommendations and the current lack of concrete evidence showing safety and/or harm. It is clear that additional epidemiologic and clinical studies are needed, especially longitudinal studies that evaluate the association between the use of different water-based (and silicone-based) lubricants and the safety and/or risk of BV, STIs, and HIV, especially in at-risk populations such as people living with HIV, MSM, and sex workers. There is also a need to assess personal lubricant safety and risk of STIs for vaginal use, as the majority of studies published thus far have been for rectal use. Iso-osmolar lubricants without nonoxynol-9 may be the best lubricant choice. Until more definitive evidence is available, in the interim it is advisable to lower STI risk by using condoms and condom-compatible lubricants, as well as practicing monogamy and testing for STIs.

Participation of each author

Cassandra Laurie performed the search and drafted the manuscript. Cassandra Laurie and Eduardo Franco critically reviewed the manuscript and approved the final version.

Funding

This work was supported by the Canadian Institutes of Health Research (foundation grant FDN-143347 awarded to ELF) and by the Cancer Research Society (operating support, grant 70302, to the Division of Cancer Epidemiology).

Conflict of interests

The authors do not have any conflicts of interest related to this work. ELF served as an occasional advisor for companies involved with HPV vaccines (Merck, GSK) and HPV diagnostics (Roche Diagnostics) and as a Steering Committee Member for a publicly funded study in Finland that received support from GSK. ELF holds a patent related to the discovery “DNA methylation markers for early detection of cervical cancer”, registered at the Office of Innovation and Partnerships, McGill University, Montreal, Quebec, Canada (October 2018). A provisional utility patent application before the United States Patent & Trademark Office was also filed (November 2018).

REFERENCES

1. K-Y Jelly buyout could push up prices of lubricant, competition watchdog warns. *The Guardian* [Internet]. 2015 [cited on 2020 Nov 20]. Available from: <https://www.theguardian.com/business/2015/may/22/k-y-jelly-buyout-lubricant-price-rise-reckitt-benckiser-johnson-johnson>
2. Herbenick D, Reece M, Schick V, Sanders SA, Fortenberry JD. Women’s use and perceptions of commercial lubricants: Prevalence and characteristics in a nationally representative sample of American adults. *J Sex Med* [Internet]. 2014 [cited 2020 Nov 11];11(3):642-52. Available from: <https://doi.org/10.1111/jsm.12427>
3. Reece M, Herbenick D, Schick V, Sanders SA, Fortenberry JD. Men’s use and perceptions of commercial lubricants: Prevalence and characteristics in a nationally representative sample of American adults. *J Sex Med* [Internet]. 2014 [cited 2020 Nov 11];11(5):1125-35. Available from: <https://pubmed.ncbi.nlm.nih.gov/24612606/> <https://doi.org/10.1111/jsm.12480>
4. Dodge B, Schick V, Herbenick D, Reece M, Sanders SA, Fortenberry JD. Frequency, reasons for, and perceptions of lubricant use among a nationally representative sample of self-identified gay and bisexual men in the United States. *J Sex Med* [Internet]. 2014 [cited 2020 Nov 11];11(10):2396-405. Available from: <https://pubmed.ncbi.nlm.nih.gov/25088090/> <https://doi.org/10.1111/jsm.12640>
5. Centers for Disease Control and Prevention (CDC). Condom Fact Sheet In Brief [Internet]. Centers for Disease Control and Prevention (CDC); 2013 [cited 2020 Nov 17]. Available from: <https://www.cdc.gov/condomeffectiveness/brief.html>
6. Golombok S, Harding R, Sheldon J. An evaluation of a thicker versus a standard condom with gay men. *AIDS* [Internet]. 2001;15(2):245-50. Available from: <http://journals.lww.com/00002030-200101260-00015>
7. Phillips DM, Zacharopoulos VR. Nonoxynol-9 enhances rectal infection by herpes simplex virus in mice. *Contraception*. 1998;57(5):341-8. [https://doi.org/10.1016/s0010-7824\(98\)00040-7](https://doi.org/10.1016/s0010-7824(98)00040-7)
8. Phillips DM, Taylor CL, Zacharopoulos VR, Maguire RA. Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. *Contraception* [Internet]. 2000 [cited 2020 Mar 23];62(3):149-54. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0010782400001566> [https://doi.org/10.1016/S0010-7824\(00\)00156-6](https://doi.org/10.1016/S0010-7824(00)00156-6)
9. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. *Lancet* [Internet]. 2002 [cited 2020 Jul 25];360(9338):971-7. Available from: <https://pubmed.ncbi.nlm.nih.gov/12383665/> [https://doi.org/10.1016/s0140-6736\(02\)11079-8](https://doi.org/10.1016/s0140-6736(02)11079-8)
10. Sudol KM, Phillips DM. Relative safety of sexual lubricants for rectal intercourse. *Sex Transm Dis* [Internet]. 2004 [cited 2020 Mar 23];31(6):346-9. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15167643> <https://doi.org/10.1097/00007435-200406000-00005>
11. Fuchs EJ, Lee LA, Torbenson MS, Parsons TL, Bakshi RP, Guidos AM, et al. Hyperosmolar Sexual Lubricant Causes Epithelial Damage in the Distal Colon: Potential Implication for HIV Transmission. *J Infect Dis* [Internet]. 2007 [cited 2020 Apr 18];195(5):703-10. Available from: <https://academic.oup.com/jid/article-lookup/doi/10.1086/511279> <https://doi.org/10.1086/511279>
12. Adriaens E, Remon JP. Mucosal Irritation Potential of Personal Lubricants Relates to Product Osmolality as Detected by the Slug Mucosal Irritation Assay. *Sex Transm Dis* [Internet]. 2008 [cited 2020 May 17];35(5):512-6. Available from: <http://journals.lww.com/00007435-200805000-00016> <https://doi.org/10.1097/OLQ.0b013e3181644669>
13. Moench TR, Mumper RJ, Hoen TE, Sun M, Cone RA. Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse. *BMC Infect Dis* [Internet]. 2010 [cited 2020 Nov 16];10:331. Available from: <https://pubmed.ncbi.nlm.nih.gov/21087496/> <https://doi.org/10.1186/1471-2334-10-331>
14. Begay O, Jean-Pierre N, Abraham CJ, Chudolij A, Seidor S, Rodriguez A, et al. Identification of Personal Lubricants That Can Cause Rectal Epithelial Cell Damage and Enhance HIV Type 1 Replication in Vitro. *AIDS Res Hum Retroviruses* [Internet]. 2011 [cited 2020 Apr 18];27(9):1019-24. Available from: <http://www.liebertpub.com/doi/10.1089/aid.2010.0252>
15. World Health Organization. Use and procurement of additional lubricants for male and female condoms: WHO/UNFPA/FHI360: advisory note [Internet]. Geneva: World Health Organization; 2012 [cited 2020 May 5]. Available from: https://apps.who.int/iris/bitstream/handle/10665/76580/WHO_RHR_12.33_eng.pdf
16. Wilkinson D, Ramjee G, Tholandi M, Rutherford G. Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. *Cochrane Database Syst Rev* [Internet]. 2002 [cited 2020 Nov 19];(4):CD003939. Available from: <https://pubmed.ncbi.nlm.nih.gov/12519623/> <https://doi.org/10.1002/14651858.cd003939>
17. Jennings PR, Bachmann L. A clinician’s guide to condoms, spermicides, microbicides, and lubricants. *J Am Acad Physician Assist* [Internet]. 2005 [cited on 2020 Nov 20];18(12):61-2. Available from: <http://journals.lww.com/01720610-200512000-00007>

18. CFR. Code of Federal Regulations Title 21 [Internet]. [cited 2020 Nov 20]. Available from: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=201.325>
19. Cunha AR, Machado RM, Palmeira-de-Oliveira A, Martinez-de-Oliveira J, Neves J, Palmeira-de-Oliveira R. Characterization of commercially available vaginal lubricants: A safety perspective. *Pharmaceutics*. 2014;6(3):530-42. <https://doi.org/10.3390/pharmaceutics6030530>
20. Ayeahunie S, Wang Y-Y, Landry T, Bogojevic S, Cone RA. Hyperosmolar vaginal lubricants markedly reduce epithelial barrier properties in a three-dimensional vaginal epithelium model. *Toxicol Reports* [Internet]. 2018 [cited 2020 May 12];5:134-40. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S221475001730118X> <https://doi.org/10.1016/j.toxrep.2017.12.011>
21. Wilkinson EM, Łaniewski P, Herbst-Kralovetz MM, Brotman RM. Personal and Clinical Vaginal Lubricants: Impact on Local Vaginal Microenvironment and Implications for Epithelial Cell Host Response and Barrier Function. *J Infect Dis* [Internet]. 2019 [cited 2020 May 5];220(12):2009-18. Available from: <https://academic.oup.com/jid/article-abstract/220/12/2009/5563809> <https://doi.org/10.1093/infdis/jiz412>
22. Hassan WM, Lavreys L, Chohan V, Richardson BA, Mandaliya K, Ndinya-Achola JO, et al. Associations Between Intravaginal Practices and Bacterial Vaginosis in Kenyan Female Sex Workers Without Symptoms of Vaginal Infections. *Sex Transm Dis* [Internet]. 2007 [cited 2020 Nov 20];34(6):384-8. Available from: <http://journals.lww.com/00007435-200706000-00010> <https://doi.org/10.1097/01.olq.0000243624.74573.63>
23. McClelland RS, Richardson BA, Graham SM, Masese LN, Gitau R, Lavreys L, et al. A prospective study of risk factors for bacterial vaginosis in HIV-1-seronegative African women. *Sex Transm Dis* [Internet]. 2008 [cited 2020 Nov 20];35(6):617-23. Available from: <https://doi.org/10.1097/olq.0b013e31816907fa>
24. Marrazzo JM, Thomas KK, Agnew K, Ringwood K. Prevalence and Risks for Bacterial Vaginosis in Women Who Have Sex With Women. *Sex Transm Dis* [Internet]. 2010 [cited 2020 Nov 20];37(5):335-9. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3291172/>
25. Brotman RM, Ravel J, Cone RA, Zenilman JM. Rapid fluctuation of the vaginal microbiota measured by Gram stain analysis. *Sex Transm Infect* [Internet]. 2010 [cited 2020 Nov 20];86(4):297-302. Available from: <https://doi.org/10.1136/sti.2009.040592>
26. Brown JM, Hess KL, Brown S, Murphy C, Waldman AL, Hezarah M. Intravaginal Practices and Risk of Bacterial Vaginosis and Candidiasis Infection Among a Cohort of Women in the United States. *Obstet Gynecol* [Internet]. 2013 [cited 2020 Nov 20];121(4):773-80. Available from: <http://journals.lww.com/00006250-201304000-00012> <https://doi.org/10.1097/AOG.0b013e31828786f8>
27. Wiesenfeld HC, Hillier SL, Krohn MA, Landers DV, Sweet RL. Bacterial vaginosis is a strong predictor of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* infection. *Clin Infect Dis* [Internet]. 2003 [cited 2020 Nov 20];36(5):663-8. Available from: <https://pubmed.ncbi.nlm.nih.gov/12594649/> <https://doi.org/10.1086/367658>
28. Chernes TL, Meyn LA, Krohn MA, Lurie JG, Hillier SL. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. *Clin Infect Dis* [Internet]. 2003 [cited 2020 Nov 20];37(3):319-25. Available from: <https://pubmed.ncbi.nlm.nih.gov/12884154/> <https://doi.org/10.1086/375819>
29. Balkus JE, Richardson BA, Rabe LK, Taha TE, Mgodini N, Kasaro MP, et al. Bacterial vaginosis and the risk of *Trichomonas vaginalis* acquisition among HIV-1-negative women. *Sex Transm Dis* [Internet]. 2014 [cited 2020 Nov 20];41(2):123-8. Available from: <https://pubmed.ncbi.nlm.nih.gov/24413493/> <https://doi.org/10.1097/olq.0000000000000075>
30. Myer L, Denny L, Telerant R, De Souza M, Wright Jr. TC, Kuhn L. Bacterial vaginosis and susceptibility to HIV infection in South African women: A nested case-control study. *J Infect Dis* [Internet]. 2005 [cited 2020 Nov 20];192(8):1372-80. Available from: <https://pubmed.ncbi.nlm.nih.gov/16170754/> <https://doi.org/10.1086/462427>
31. Gorbach PM, Weiss RE, Fuchs E, Jeffries RA, Hezarah M, Brown S, et al. The Slippery Slope: Lubricant Use and Rectal Sexually Transmitted Infections: A Newly Identified Risk. *Sex Transm Dis* [Internet]. 2012 [cited 2020 Apr 18];39(1):59-64. Available from: <http://journals.lww.com/00007435-201201000-00014> <https://doi.org/10.1097/OLQ.0b013e318235502b>
32. Maierhofer C, Rice CE, Wang SH, Fields KS, Ervin M, Turner AN. Lubricant use and rectal chlamydial and gonococcal infections among men who engage in receptive anal intercourse. *Sex Transm Dis*. 2016;43(7):423-8. <https://doi.org/10.1097/olq.0000000000000463>
33. Blair CS, Javanbakht M, Comulada WS, Richter EI, Bolan R, Shoptaw S, et al. Lubricants and rectal douching: associations with rectal gonorrhea, chlamydia, and/or syphilis infection among men who have sex with men. *Int J STD AIDS* [Internet]. 2020 [cited 2020 Nov 16];31(11):1040-6. Available from: <http://journals.sagepub.com/doi/10.1177/0956462420938485>
34. Ward H, Rönn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. *Curr Opin HIV AIDS* [Internet]. 2010 [cited 2020 Nov 19];5(4):305-10. Available from: <https://doi.org/10.1097/coh.0b013e32833a8844>
35. Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. *Lancet Infect Dis* [Internet]. 2017 [cited 2020 Nov 19];17(12):1303-16. Available from: [https://doi.org/10.1016/s1473-3099\(17\)30405-x](https://doi.org/10.1016/s1473-3099(17)30405-x)
36. Looker KJ, Rönn MM, Brock PM, Brisson M, Drolet M, Mayaud P, et al. Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV. *J Int AIDS Soc* [Internet]. 2018 [cited 2020 Nov 19];21(6):e25110. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jia2.25110> <https://doi.org/10.1002/jia2.25110>
37. Dezzutti CS, Brown ER, Moncla B, Russo J, Cost M, Wang L, et al. Is Wetter Better? An Evaluation of Over-the-Counter Personal Lubricants for Safety and Anti-HIV-1 Activity. *PLoS One*. 2012;7(11):e48328. <https://doi.org/10.1371/journal.pone.0048328>
38. Vishwanathan SA, Morris MR, Wolitski RJ, Luo W, Rose CE, Blau DM, et al. Rectal application of a highly osmolar personal lubricant in a macaque model induces acute cytotoxicity but does not increase risk of SHIV infection. *PLoS One* [Internet]. 2015 [cited 2020 Apr 20];10(4):e0120021. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25853710> <https://doi.org/10.1371/journal.pone.0120021>
39. Rao A, Ewing W, Ketende S, Wirtz AL, Jumble V, Trapence G, et al. Correlates of Water-Based Lubricant Use Among Men Who Have Sex with Men in Blantyre, Malawi. *AIDS Res Hum Retroviruses* [Internet]. 2019 [cited 2020 Nov 13];35(9):833-41. Available from: <https://doi.org/10.1089/aid.2018.0287>
40. World Health Organization. United Nations Population Fund. Global consultation on personal lubricants meeting report [Internet]. Geneva: World Health Organization; 2016 [cited 2020 Nov 16]. Available from: https://cdn.shopify.com/s/files/1/2673/6210/files/Meeting_Report_Global_Consultation_on_Personal_Lubricants.pdf
41. World Health Organization. United Nations Population Fund. Specifications for plain lubricants (July 2019). Draft for comments [Internet]. Geneva: World Health Organization; 2019 [cited 2020 Nov 15]. Available from: https://www.who.int/medicines/areas/quality_safety/quality_assurance/QAS19_806_specifications_for_plain_lubricants.pdf?ua=1

Address for correspondence:

CASSANDRA LAURIE

Division of Cancer Epidemiology, McGill University
5100 Maisonneuve Blvd West, Suite 720
Montreal, QC, H4A 3T2, Canada
E-mail: cassandra.laurie@mail.mcgill.ca

Received on: 11.23.2020

Approved on: 11.25.2020